Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxARDX -17.86%68 EV-to-OCF is -55.33 as of Aug. 08, 2026. GuruFocus rates ARDX with a GF Score™ of 68/100 and a GF Value™ of $8.86 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,409 Biotechnology companies, Ardelyx ranks better than 87.93% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ardelyx's Enterprise Value is $958.3 Mil.
Ardelyx's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-17.3 Mil. Therefore, Ardelyx's EV-to-OCF for today is -55.33.
The historical rank and industry rank for Ardelyx's EV-to-OCF or its related term are showing as below:
ARDX'
s EV-to-OCF Range Over the Past 10 Years
Min: -45.82 Med: -4.34 Max: 0.7
Current: -26.43
During the past 13 years, the highest EV-to-OCF of Ardelyx was 0.70. The lowest was -45.82. And the median was -4.34.
ARDX's EV-to-OCF is ranked better than 87.93% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs ARDX: -26.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ardelyx's share price for today is $4.00.
Ardelyx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ardelyx EV-to-OCF Related Terms
Ardelyx EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Ardelyx's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ardelyx's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ardelyx's EV-to-OCF falls into.
Ardelyx's current Enterprise Value is $958.3 Mil.
Ardelyx's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (ARDX) has a EV-to-OCF of -55.33 as of Aug. 08, 2026. According to the industry distribution chart, Ardelyx ranks #170 out of 1409 companies in the Biotechnology industry, placing it in the top 12.1%.
Is Ardelyx's EV-to-OCF too high?
Ardelyx's current EV-to-OCF is -55.33. Based on the distribution chart, Ardelyx ranks #170 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ardelyx has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's EV-to-OCF compare to IMTX and TRAX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #170 out of 1409 companies for EV-to-OCF. This places Ardelyx in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ardelyx's current EV-to-OCF is -55.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $8.86, compared to a current price of $4.00 — trading 54.9% below its estimated fair value. The current EV-to-OCF is -55.33. Ardelyx's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ardelyx (ARDX), the current EV-to-OCF is -55.33 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of $4.00 is trading 54.9% below its estimated GF Value™ of $8.86.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for ARDX:
EV-to-OCF: -55.33
GF Value™: $8.86 vs. price of $4.00 (54.9% below fair value)
No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
68GF Score
Get the complete analysis for ARDX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDX has been successfully added to your 
